Investment Thesis
Psychemedics exhibits deteriorating operational fundamentals with declining revenue (-10.9% YoY) and persistent operating losses (margin -9.6%), despite positive free cash flow and a debt-free balance sheet. The company's improving net income is masked by worsening EPS (-58.3% YoY), signaling deepening per-share earnings erosion that requires either significant revenue recovery or substantial cost restructuring to restore viability.
Strengths
- Positive free cash flow of $878K despite net losses, indicating disciplined capital management
- Strong liquidity with current ratio of 1.82x and cash position of $1.4M providing operational cushion
- Zero debt and positive stockholders' equity of $5.1M with solid balance sheet foundation
- Decent gross margin of 36.1% suggests pricing power in medical laboratory services segment
Risks
- Revenue decline of 10.9% YoY indicates lost market share or reduced demand in competitive medical lab sector
- Deeply negative operating margin of -9.6% shows core business is unprofitable before financing costs
- Deteriorating EPS (-58.3% YoY) despite improving net income reveals unfavorable share dilution and shareholder value destruction
- Limited cash runway relative to persistent operating losses if revenue decline accelerates further
Key Metrics to Watch
- Revenue growth rate reversal from negative to positive territory
- Operating margin improvement toward breakeven and profitability thresholds
- Free cash flow sustainability as cash reserves deplete from ongoing losses
- Gross margin stability or expansion to offset operating leverage pressures
Financial Metrics
Revenue
19.7M
Net Income
-1.9M
EPS (Diluted)
$-0.56
Free Cash Flow
878.0K
Total Assets
8.3M
Cash
1.4M
Profitability Ratios
Gross Margin
36.1%
Operating Margin
-9.6%
Net Margin
-9.5%
ROE
-36.3%
ROA
-22.4%
FCF Margin
4.5%
Balance Sheet & Liquidity
Current Ratio
1.82x
Quick Ratio
1.82x
Debt/Equity
0.00x
Debt/Assets
38.3%
Interest Coverage
-72.81x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-14T10:33:25.118911 |
Data as of: 2024-12-31 |
Powered by Claude AI